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Abstract
Belinostat is a hydroxamate class HDAC inhibitor that has demonstrated activity in peripheral T-cell lymphoma and is
undergoing clinical trials for non-hematologic malignancies. We studied the pharmacokinetics of belinostat in
hepatocellular carcinoma patients to determine the main pathway of metabolism of belinostat. The pharmacokinetics of
belinostat in liver cancer patients were characterized by rapid plasma clearance of belinostat with extensive metabolism
with more than 4-fold greater relative systemic exposure of major metabolite, belinostat glucuronide than that of
belinostat. There was significant interindividual variability of belinostat glucuronidation. The major pathway of metabolism
involves UGT1A1-mediated glucuronidation and a good correlation has been identified between belinostat glucuronide
formation and glucuronidation of known UGT1A1 substrates. In addition, liver microsomes harboring UGT1A1*28 alleles
have lower glucuronidation activity for belinostat compared to those with wildtype UGT1A1. The main metabolic pathway
of belinostat is through glucuronidation mediated primarily by UGT1A1, a highly polymorphic enzyme. The clinical
significance of this finding remains to be determined.Trial Registration: ClinicalTrials.gov NCT00321594 http://clinicaltrials.
gov/ct2/show/NCT00321594
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Introduction
Histone deacetylase inhibitors (HDACis) have been shown to
have anticancer activity in malignant cells through acetylation of
both histone and non-histone proteins. Acetylation of histones
mediates epigenetic modulation of genes that can induce
apoptosis, inhibit cell growth and reduce neoangiogenesis [1–7].
Several HDACis have been approved for treatment of peripheral
or cutaneous T-cell lymphoma [8–10].
Belinostat is a hydroxamic acid based pan-histone deacetylase
inhibitor in clinical development as an anti-cancer therapy in a
range of hematological and solid malignancies, both as single
agent as well as combination therapies [11–18]. Currently
belinostat has been granted fast track and orphan drug designation
by the U.S. Food and Drug Administration for treatment of
relapsed or refractory peripheral T-cell lymphoma. Although
clinically the drug has been relatively well tolerated, the common
adverse events included fatigue, nausea and vomiting, and
lethargy, reaching grade 3 at the maximum tolerable dose of
1200 mg/m2 given in 30 minute (min) infusions for 5 consecutive
days every 3 weeks. Belinostat is available in both oral and
intravenous formulations, and as the drug is expected to be
administered on a chronic basis, cumulative toxicities are possible.
Therefore, it would be important to determine the metabolism of
belinostat, to understand its in vivo disposition. Up till now, very
little is known about the metabolic pathways of belinostat.
Other members of the hydroxamic acid class HDAC inhibitors
like vorinostat and panobinostat undergo primary metabolism by
glucuronidation [19–21]. On the other hand, romidepsin, a cyclic
tetrapeptide class HDAC inhibitor, undergoes metabolism mainly
by CYP3A4 [22]. Therefore, we hypothesized that glucuronida-
tion would be the primary pathway for metabolism of belinostat.
Furthermore, many glucuronosyl transferase isoforms are highly
polymorphic and impact function, for example, homozygous
deletion of UGT2B17 alleles (UGT2B17*2) results in defective
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metabolism of vorinostat [23]. Accordingly, it would be important
to identify the main drug metabolizing isoform of belinostat, to
better understand the influence of pharmacogenetics on the
interindividual variability of belinostat pharmacodynamics. This
also provides guidance for further drug interaction studies.
In this study, we studied the pharmacokinetics of belinostat and
identified its metabolites based on the mass spectra and maximum
UV absorption. We identified the dominant metabolite of
belinostat as belinostat glucuronide, and further studied the
glucuronidation of belinostat using a panel of UGT isoenzymes
and human liver microsomes, to determine the main isoform
responsible for its metabolism. Finally, potential pharmacogenetic
influence on pharmacodynamics of belinostat was explored.
Materials and Methods
The protocol for this trial is available as supporting information;
see Protocol S1.
Reagents
Belinostat (PXD101) was a gift from the National Cancer
Institute (Bethesda, MD, USA). Belinostat glucuronide (belinostat-
G) was chromatographically separated with HPLC–UV and
isolated from human plasma using a fraction collector. Its
chemical structure and purity has been verified through LC-
MS/MS (API 4000 triple-quadrupole mass spectrometer; AB
Sciex, Concord, Canada) and HPLC-UV analysis. Vorinostat
glucuronide (vorinostat-G), the internal standard, was a gift from
Merck Sharp & Dohme (I.A.) Corp. Acetonitrile (HPLC grade),
methanol (HPLC grade), ethanol (analytical grade), formic acid
(analytical grade), di-sodium hydrogen phosphate dihydrate
(Na2HPO4.2H2O) and orthophosphoric acid (85%) were obtained
from Merck (Darmstadt, Germany). Direct-QTM water (Millipore
Milford, MA, USA) was used for the mobile phase preparation.
Human UGT supersomes and UGT Reaction-Solutions A and B
were purchased from BD Gentest (San Jose, CA, USA). These are
cDNA expressed UGTs and a panel of 12 (UGT1A1, UGT1A3,
UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10,
UGT2B4, UGT2B7, UGT2B15, UGT2B17) was used.
Human Liver Microsome Preparation
Human livers from 37 normal Caucasian donors were processed
in Dr. Mary Relling’s laboratory at St. Jude Children’s Research
Hospital (Memphis, TN, USA) and were provided by the Liver
Tissue Procurement and Distribution System (funded by #N01-
DK-9-2310) and by the Cooperative Human Tissue Network. The
37 human liver microsomes (HLM) were isolated from different
liver specimen with no correlation each other. Microsomes were
prepared by differential centrifugation.
Study Cohorts
This multicentre phase I trial of belinostat was done in Hong
Kong and Singapore. All patients provided written informed
consent according to Good Clinical Practice guidelines, and the
protocol was approved by the institutional review boards of Prince
of Wales Hospital, Hong Kong and National University Hospital,
Singapore. Seventeen patients were treated with belinostat at
escalating doses of 600 (n = 3), 900 (n = 3), 1,200 (n= 6), 1,400
(n = 5) mg/m2 daily by intravenous (i.v.) infusion over 30 min for 5
days every 21 days.
Pharmacokinetic Assessment
Blood specimens were collected at predetermined sampling time
points on day 1 at predose, 15 min, 30 min, 45 min, 1 hour (h),
1.5 h, 2 h, 3 h, 5 h and 24 h postinfusion and day 5 at predose,
30 min, 1 h, 1.5 h, 3 h, 5 h postinfusion and day 22 following the
start of 30 min i.v. infusion in a phase I clinical trial of belinostat.
Venous blood samples had been collected in heparinized tubes.
Collected blood samples were centrifuged at 3000 g for 10–15 min
and the plasma (supernatant) was separated from the cell pellet
and stored in plain tubes at –80uC till analysis. The concentrations
of belinostat and belinostat glucuronide were quantified by a
modified high-performance liquid chromatography/mass spec-
trometry method [24]. Briefly, vorinostat-G was used as the
internal standard for belinostat-G. The mass spectrometer was
operated in positive ion mode with the optimal mass transitions of
belinostat-G: m/z 495.93 and vorinostat-G: m/z 441.232,
respectively. The analytical method was well validated with good
linearity (coefficient of determination, r2$0.999) in the range of 1–
100 mM for belinostat-G.
Identification of Belinostat Metabolites and Isolation
of Belinostat-G
Metabolite screening in patient samples was processed with
HPLC-UV at 268 nm, the maximum absorption wavelength of
belinostat. Baseline separation of all the analytes was achieved on
the Alltima C18 (150 mm62.1 mm, 5 mm) column. Mobile phase
solvent A was 20 mM Na2HPO4 (pH 4.2, adjusted by orthophos-
phoric acid), while mobile phase solvent B comprised of 70%
acetonitrile and 30% methanol (v/v). A gradient mobile phase
programme was used – initial percentage of solvent A was 75% (v/
v) and that of solvent B was 25% (v/v); percentage of solvent B was
increased to 95% (v/v) over 13 min and immediately switched
back to 25% (v/v) for 7 min before injection of the subsequent
sample. Total run time of each sample was 25 min. The flow rate
was maintained at 0.5 mL/min.
The potential belinostat metabolites were further verified with a
tandem mass spectrometer in Q1, product and precursor scans.
The isolation and purification of the major metabolite of belinostat
was performed on a Nova-Pak 3.96300 mm C18 column (Waters,
Ireland), using 20 mM ammonium acetate buffer (pH 5.0) and
100% methanol in an initial mobile phase composition of
60%:40% (v/v) with a flow rate of 0.6 mL/min. Methanol was
increased to 95% over 10 min and immediately switched back to
40% for 6 min before the next injection. b-Glucuronidase
hydrolysis and mass spectrometry (both in positive and negative
mode) to ascertain purity and identity of the major metabolite.
Acidic Stability Test for Belinostat-G
1 mg/mL of belinostat-G and vorinostat-G was prepared in
various vehicles with different pH values. These vehicles included
10 mM ammonium acetate (pH=6.5), 10 mM ammonium
formate (pH=6.0), 0.1% acetic acid (pH=3.2) and 0.1% formic
acid (pH=2.6). All of these test samples were incubated at 37uC
for 24 h. Milli Q water (pH=5.5) was used as control solution
which was stored in220uC. All the samples were analyzed by LC-
MS/MS to obtain the values of peak area for belinostat-G and
vorinostat-G. The acidic stability of both conjugated compounds
was evaluated through comparison of peak area ratio of test
samples versus control.
In Vitro Potency Assessment on
Belinostat and Belinostat-G
To determine the presence or absence of dose-dependent
activity of belinostat and belinostat-G against hepatocellular
cancer cells, human hepatocellular liver carcinoma (HepG2) cells
were seeded in two 24-well plates at 10,000 cells per well. To one
Metabolic Disposition of Belinostat
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plate, 5 different concentrations of belinostat were added to obtain
2 replicates per concentration (0.1, 0.5, 1, 2, 5, 10 mM). To the
other plate, equal molar concentrations of belinostat-G were
added similarly. After 72 h, cells were stained with Gentian Violet
paint (0.5% w/v; B.P.) and assessed for viability. Furthermore, the
sensitivities of HepG2 to belinostat and belinostat-G were
quantitatively measured using the MTS assay. In brief, HepG2
cells seeded in 96-well plates at 3,000 cells/well were treated with
seven different doses of belinostat or belinostat-G and then
assessed for growth inhibition with Promega CellTiter 96H
AQueous Non-Radioactive Cell Proliferation Assay. After incubat-
ing 24 h, 100-mL drug solution or blank medium was added into
each well of 96-well plates. 72 h later, 20 mL of MTS/PES was
added into each well for incubation for 3 h. OD values are
measured on wavelength 490 nm. Cell growth inhibition was
calculated based on the luminescent units with subtraction of
background reading for only medium containing wells. The
growth inhibition was defined as the percentage of the average
luminescent units from drug-treated wells over that from control
wells without treatment. The experiment was done in triplicates.
IC50 values were calculated using GraphPad PRISM software
(GraphPad Software, Inc., La Jolla, CA, USA).
Western Blotting
For western blot analysis, the HepG2 cells treated with
belinostat were harvested and lysed in cell lysis buffer containing
50 mM Tris HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1%
TRITON X-100 (Sigma-Aldrich) and protease inhibitor cocktail
(Roche). Protein concentrations were quantified using the
Bradford assay (Invitrogen). Proteins were separated on a 12%
SDS-PAGE gel and transferred to nitrocellulose membrane.
Nonspecific protein binding was blocked by incubating with 5%
non-fat milk (BioRad Laboratories) in 0.1% PBS-Tween (PBST) at
room temperature for 1 h and incubated with specific antibodies,
Histone H3 and Ac-H3 [K9/K14] (Cell Signaling), at 4uC
overnight. Appropriate species-specific Horseradish peroxidises-
conjugated secondary antibodies were then added and incubated
at room temperature for 1 h followed by detection using an
enhanced chemiluminescence kit (GE Healthcare).
Screening of 12 Human UGT Supersomes and Kinetic
Analysis
A typical incubation consisted of 50 mg of UGT, 2 mM
UDPGA (UGT Reaction Solution A), 50 mM Tris-HCl, 8 mM
MgCl2 and 0.025 mg/ml alamethicin (UGT Reaction Solution B)
in a final incubation volume of 100 mL. Before the addition of
substrate, the incubation mixture was prewarmed and equilibrated
for 5 min at 37uC. Reactions were initiated by addition of 10 mM
belinostat solution in DMSO and incubated at 37uC for 30 min;
the reactions were terminated by adding 200 mL of ice-cold
methanol and vortexing. The incubation mixture was vortexed
and centrifuged (10,060 g) at 4uC for 10 min, and the supernatants
were analyzed. Insect microsomes without UGT cDNA served as
negative control. Kinetic parameters (Km and Vmax) of belinostat
glucuronidation by UGT1A1 supersomes were determined using
substrate concentrations of 10 to 750 mM. Incubations were
performed as described above. Three independent experiments
were performed for kinetic analysis.
Correlation Study with UGT1A1 Substrates, UGT1A1 Gene
Expression and UGT1A1*28 Polymorphism
In a correlation study of glucuronidation of belinostat and
UGT1A1 substrates, belinostat glucuronidation was measured as
described above using 100 mM belinostat and 50 mg HLM; this
concentration of belinostat was selected as it is close to the Km of
UGT1A1. Glucuronidation of bilirubin, thyroxine and SN-38 in
these microsomes, measurement of UGT1A1 gene expression and
genotyping for UGT1A1*28 have been previously described [25–
27].
Data Analysis
Belinostat-G formation velocity (v) was calculated as Cm,
30 min/incubation time/CYP concentration, where Cm, 30 min
was the metabolite concentration after 30 min incubation. Plots of
substrate concentration, S (X axis) versus v (Y axis) were then
constructed. Km and Vmax were calculated using the Michaelis-
Menten equation (GraphPad software, Inc., San Diego, CA,
USA).
v~½S|Vmax=(½SzKm) ð1Þ
Association between belinostat glucuronide concentration and
UGT1A1 substrates were performed using both Pearson’s
correlation and Spearman’s correlation tests (GraphPad Prism
software, La Jolla, CA). Pharmacokinetic parameters were
estimated based on non-compartmental analysis model using
WinNonlin software version 5.3 (Pharmsight, Sunnyvale, CA,
USA). Relative exposure of belinostat-G in patient plasma was
represented by the molar concentration AUC ratio of belinostat-G
over belinostat. One way analysis of variance (ANOVA) was used
to determine the significance among the genotypes with Tukey
posthoc tests for adjustment for comparison between individual
groups. A value of p,0.05 was considered to be significant.
Results
Pharmacokinetics and Metabolism of Belinostat in
Human Plasma
The concentrations of belinostat and belinostat-G in 17 patients
enrolled in a phase I clinical trial in hepatocellular carcinoma
(HCC) were quantified for estimation of pharmacokinetic param-
eters (Table 1). Belinostat followed linear pharmacokinetics at
doses ranging from 600 to 1400 mg/m2, with larger interindivid-
ual variability of clearance at higher doses. The coefficients of
variation of Clearance (CL) were 29.0% and 30.6% at 1200 and
1400 mg/m2, respectively. Belinostat was eliminated rapidly after
i.v. administration due to intensive phase II glucuronide conjuga-
tion, M1 (Figure 1).
Five metabolites of belinostat were identified through compar-
ing the ultraviolet (UV) absorption of plasma samples at 268 nm
before and after dosing. Similar chromatogram profiles were
detected on day 1 (Figure 1B) and day 5 (Figure 1A). The MS/MS
product ions of these five metabolites monitored in positive mode
supported their chemical structure identification (Table 2).
Glucuronidation was the most significant pathway of belinostat
metabolism; two alternate biotransformation pathways involved
methylation to methyl belinostat and reduction of the hydroxamic
group to its corresponding belinostat amide. Belinostat acid and
belinostat glucoside were 2 other minor metabolites detected. The
proposed metabolic pathway of belinostat is indicated in Figure 2.
The chemical structures of these metabolites are proposed based
on their protonated molecule mass peaks [M+H] +, 2-fold
molecule mass peaks [2M+H] +and mass fragmentation profiling
generated by product scan. These structures were further
confirmed by analysis of fragmentation ions of precursor ions,
which revealed a common product ion (m/z 93, phenylamino
Metabolic Disposition of Belinostat
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fragment) of belinostat and its five metabolites. Based on the
metabolite structures, the hydroxamide moiety is the key structure
for the potency of belinostat. Scanning of m/z spectra from the
plasma of patients supported glucuronidation of belinostat through
detection of 495, 989, 493 representing the protonated belinostat
G, protonated double belinostat G, and deprotonated belinostat
G, respectively. The chemical structure of belinostat-G isolated
from plasma was elucidated by mass spectrometry. A series of mass
spectra of belinostat-G were acquired to propose the chemical
structure. For instance, m/z 495 and m/z 989 were identified as
its protonated molecule mass peaks [M+H]+ and 2-fold molecule
mass peaks [2M+H]+, respectively. Scanning in negative mode
detected its corresponding deprotonated parent ion as m/z
493[M-H]–. A similar mass fragmentation profiling in positive
mode was found both for belinostat and belinostat-G. Based on the
common product ion (phenylamino fragment), a precursor ion
scan of m/z 93 was processed on belinostat and belinostat-G to
derive their parent ions as m/z 319 [M+H]+ for belinostat and m/
z 495 [M+H]+ for belinostat-G, respectively. Assuming this was
correct, the chemical structures of its metabolites would be
expected to possess similar UV spectra for these metabolites and its
parent compound as well due to similarity on their basic molecular
structures, and this was supported by UV spectral analysis
generated by diode array detector (DAD) showing similar
maximum wavelength at 268 nm for belinostat and its five
metabolites.
The major metabolite was identified as belinostat-G which was
further confirmed through enzyme hydrolysis reaction. The
Figure 1. Identification of belinostat metabolites in human plasma using HPLC-UV at maximum absorption wavelength
(l=268 nm). Chromatogram at day 5 and day 22 (A); day1(B).
doi:10.1371/journal.pone.0054522.g001
Table 1. Pharmacokinetic parameters for belinostat after 30 min i.v. infusion in Phase I trial.
Substance Parameter* 600 mg/m2 900 mg/m2 1200 mg/m2 1400 mg/m2
Belinostat No. of Patients 3 3 6 5
Cmax, mmol/L 88.268.5 98.5629.7 153.5650.4 174.4648.3
Tmax, h 0.3360.14 0.4260.14 0.6460.10 0.4060.14
AUC0–24 h, h6 mmol/L 61.361.2 70.0617.3 112.6637.1 149.0646.2
T1/2, h 3.5460.34 4.0760.39 4.1460.42 3.5460.50
CL, L/h 52.663.8 70.5617.9 54.6615.8 53.0616.2
Vz, L 268.3626.6 409.2676.7 304.96185.6 279.16120.8
Belinostat-G AUC0–24 h, h6 mmol/L 286.5636.6 302.1654.8 514.1641.4 575.16154.0
Relative Exposure Bel-G/Bel AUC ratio 4.7960.46 4.2260.15 4.8261.80 4.1360.68
Abbreviation: Cmax, maximum concentration; Tmax, time to maximum concentration; AUC0–24 h, area under the curve from 0 to 24 h; T1/2, half-life at the elimination
phase; CL, clearance; Vz, volume of distribution. *Mean 6 SD; AUC ratio was calculated based on AUC0–24 h of Bel-G (belinostat-G) over AUC0–24 h of Bel (belinostat).
doi:10.1371/journal.pone.0054522.t001
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isolated belinostat-G from patient plasma samples was subjected to
Escherichia coli-derived b-glucuronidase (6.8 mg/mL) incubation
for 5 h, and the resulting reaction mixture was analyzed through
LC-MS/MS. The quantitative pharmacokinetic analysis indicated
that belinostat-G exposure was 4-fold higher than that of
belinostat in human plasma based on the molar concentration
AUC ratio of belinostat-G/belinostat (Table 1). Hence, belinostat
glucuronidation was confirmed to be the dominant metabolic
pathway for belinostat.
Stability of Belinostat-G in Acidic Environment
To further characterize the glucuronidation of belinostat, we
tested the acidic stability of belinostat-G. Belinostat-G and
vorinostat-G, a parallel control for belinostat-G, were demon-
strated to be stable after 24 h incubation at 37uC in various acidic
solutions (pH 2.6– pH 6.5). The variation in concentrations
measured at the beginning of the experiment and after 24 h was
very marginal (,4%). This is consistent with our proposed O-
conjugated structure of belinostat-G (M1) shown in Figure 2.
However, minor degradation (7%) was identified only when the
pH value was decreased to 2.6. The results confirmed belinostat is
conjugated to glucuronide at the O position, as O-glucuronides
but not N-glucuronides of hydroxamic acids are stable in acidic
environment [28,29]. As vorinostat-G has been confirmed to be an
O-conjugated glucuronide [30], it demonstrates that the isolated
belinostat-G is an O-conjugated metabolite as well.
Determination of In Vitro Cytotoxicity Effects of
Belinostat and Belinostat-G
Figure 3a and 3b show the results of dose-increasing concen-
trations of belinostat and belinostat-G conducted on separate 24-
well plates after incubation for 72 h. As belinostat concentration
increased, number of viable cells (stained violet) showed dose-
dependent decrease. Conversely, increasing concentrations of
belinostat-G did not seem to affect cell viability within the
concentration range tested. As such, at equimolar concentrations
between 0–10 mM, belinostat demonstrates significant dose-
dependent cytotoxicity while belinostat-G does not. Furthermore,
the results of MTS assays were also consistent with that of the
staining assay (Figure 3c). Histone H3 acetylation for belinostat
exposure demonstrated a time and concentration dependent
increase (Figure 3d).
Figure 2. Belinostat metabolism pathway in human plasma with glucuronidation of belinostat as the dominant metabolism.
doi:10.1371/journal.pone.0054522.g002
Table 2. Identification of belinostat metabolites in human plasma using HPLC-DAD & LC-MS/MS analyses.
Peak ID Retention Time (min) l (nm) [M+H] + MS/MS Proposed Structure
Belinostat 11.5 268 319 93, 204, 268, 286 Parent compound
M1 16.8 268 495 93, 204, 268, 286, 319 Belinostat glucuronide
M2 12.1 268 303 93, 204, 268, 286 Belinostat amide
M3 13.0 268 333 93, 204, 268, 286 Methyl belinostat
M4 15.1 268 304 93, 268, 286,319 Belinostat acid
M5 10.9 268 481 93, 204, 268, 286, 319 Belinostat glucoside
doi:10.1371/journal.pone.0054522.t002
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In Vitro Metabolism Screening of UGTs for Belinostat-G
Formation and Enzyme Kinetics
UGT1A1 glucuronidated belinostat significantly (Figure 4A),
whereas no metabolism was observed after incubation with
UGT1A4, UGT1A6, UGT1A7, UGT1A9, UGT1A10,
UGT2B15 and UGT2B17. Minor metabolism (less than 3%)
was detected with UGT1A3, UGT1A8, UGT2B4 and UGT2B7.
73.6% and 89.4% of belinostat was converted to belinostat-G after
2 h and 4 h of incubation with UGT1A1, respectively (Figure 4B).
Enzyme kinetic parameters for the glucuronidation of belinostat
were estimated by fitting the pooled data from the UGT1A1
incubations performed in triplicate to the Michaelis-Menten
equation. The apparent Km and Vmax values for the glucuronide
formation were 99.6 mM and 353.1 pmol/min/mg protein,
respectively (Figure 5). The intrinsic clearance (Vmax/Km) for
formation of belinostat-G was estimated to be 3.5 mL/min/mg
protein. In the control insect microsomes, no belinostat-G
formation was observed.
Correlation of Glucuronidation of Belinostat with UGT
Substrates
In human liver microsomes, the association between glucur-
onidation of belinostat and UGT substrates were tested using
parametric (Person’s correlation) and non-parametric (Spearman’s
correlation) tests. Belinostat-G formation correlated strongly with
bilirubin glucuronide formation (Figure 6A) (Pearson r2 = 0.53;
Spearman r2 = 0.61 p,0.0001) and other well established
substrates of UGT1A1 like thyroxine and SN38 (Pearson
r2 = 0.68; Spearman r2 = 0.81 and Pearson r2 = 0.82; Spearman
r2 = 0.62, respectively, all p,0.001) (Figure 6B, and 6C).
Belinostat-G concentrations after incubation with the HLM
correlated well with UGT1A1 mRNA expression (Pearson,
r2 = 0.66, p,0.0001, Figure 7A). Taken together, these suggest
that UGT1A1 is the predominant UGT isoform in belinostat
glucuronidation.
Figure 3. Cytotoxicity and acetylation activity on HepG2. a: belinostat incubation; b: belinostat-G incubation; (templates for concentrations
added (lower) and results of 24-well dose-increasing concentrations on HepG2 Cells (upper). c: MTS results for belinostat (IC50 = 6.4 mM) and
belinostat-G (cannot be converged). d:Belinostat acetylation activity on HepG2 cells (western blot). A: Acetyl histone 3 increased with dose increment
after 5 h incubation; B: Kinetic changes of acetyl histone 3 with time increment at 10 mM.
doi:10.1371/journal.pone.0054522.g003
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UGT1A1 Genotype and Glucuronidation of Belinostat in
Human Liver Microsomes and Correlation with UGT1A1
Gene Expression
UGT1A1 is a polymorphic enzyme with allelic variants that
influence its enzymatic activity. UGT1A1*28 is a frequent
polymorphism that reduces glucuronidation activity. Therefore,
to determine the effect of UGT1A1*28 on formation of belinostat-
G, we measured belinostat-G concentrations after incubation of
belinostat with each of 37 HLM samples previously genotyped for
UGT1A1*28. The 30-min post-incubation belinostat-G concen-
trations (mean 6 SD) were 15.3966.00, 11.3564.11 and
7.1463.28 mmol for UGT1A1*1 homozygous, UGT1A1*28
heterozygous and homozygous microsomes, respectively. One
way ANOVA analysis showed that significant difference between
groups was detected (p = 0.01). Tukey posthoc analysis suggested
that only the difference between UGT1A1*1 and UGT1A1*28
homozygous microsomes was statistically significant. As shown in
Figure 7B, UGT1A1*1 homozygous microsomes had 2 fold
greater mean belinostat-G concentrations compared to
UGT1A1*28 homozygous microsomes after incubation (p,0.001).
Discussion
To our knowledge, this is the first report describing the
glucuronidation of belinostat. We have demonstrated that
belinostat undergoes extensive metabolism through glucuronida-
Figure 4. Enzyme stability test in a panel of 14 UGT isoforms after 2 h incubation at 376C (A); Time course of glucuronidation of
belinostat by UGT1A1supersomes at 376C (B).
doi:10.1371/journal.pone.0054522.g004
Figure 5. Enzyme kinetics of glucuronidation of belinostat by
UGT1A1. The apparent Km and Vmax values for the glucuronide
formation were 99.6 mM and 353.1 pmol/min/mg protein, respectively.
doi:10.1371/journal.pone.0054522.g005
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tion occurring at the hydroxamate moiety, leading to inactivation
of its cytotoxicity. This is consistent among other hydroxamate
class HDAC inhibitors as well, where glucuronidation plays a
significant role in their metabolism. The metabolite profiling after
incubation with a panel of supersomes overexpressing specific
UGT isoforms, correlation with glucuronidation rates of known
UGT1A1 substrates using human liver microsomes, and analysis
of the mass spectrometry profile of belinostat in a cohort of
patients with liver cancer provided evidence that belinostat
glucuronidation in vitro and in vivo is mediated primarily by
UGT1A1. Interestingly, the enzyme isoform that primarily
metabolises another hydroxamic based HDAC inhibitor vorinostat
in vivo is UGT2B17, whereas belinostat is metabolised by
UGT1A1, which is a more abundant isoform in the human liver
[31]. UGT1A1 is present in the gastrointestinal tract, which would
likely reduce oral absorption of belinostat, and lead to reduced
bioavailability [32]. In addition, the high efficiency of UGT1A1
for metabolising belinostat will likely reduce further its oral
bioavailability through extensive first pass metabolism, posing a
challenge to development of oral belinostat.
The HDAC inhibitors that are in clinical development have
potential for serious side effects. Some class related effects include
thrombocytopenia, prolonged QT interval on the electrocardio-
gram,severe fatigueandgastrointestinal sideeffects,andtheseappear
to be dose dependent. Belinostat has been associated with fatigue,
diarrhea and prolongation of QT interval in phase I and II trials
[11,33]. In view of its narrow therapeutic window, it is important to
determine the factors such as pharmacogenetics of belinostat that
account for interindividual variability of its pharmacokinetics. We
previously showed that patients with deleted UGT2B17 alleles have
lower vorinostat-glucuronide to vorinostat area-under-the-curve
ratio andgreater side effects [20].Accordingly, itwouldbe important
to understand the extent of interindividual variability of belinostat
pharmacokinetics and pharmacodynamics attributable to polymor-
phic expressionofUGT1A1.Our study inhuman livermicrosomes is
the first step in this direction.
Figure 6. Association between glucuronidation of belinostat and UGT1A1 substrates (A, B, and C). A: Bilirubin-G; B: thyroxine-4-G/CPT-
11; C: SN38-G/CPT11.
doi:10.1371/journal.pone.0054522.g006
Figure 7. UGT1A1 expression on belinostat glucuronidation and impact of the common UGT1A1*28 promoter polymorphism. A:
Correlation of belinostat glucuronide formation with UGT1A1 expression in human liver microsomes; B: Belinostat glucuronide formation by human
liver microsomes according to wild-type, heterozygous and homozygous UGT1A1*28 genotypes.
doi:10.1371/journal.pone.0054522.g007
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UGT1A1*28 is a genetic polymorphism at the promoter region
where an additional TA repeat is present in the TATA box that
usually has 6 TA repeats, and results in reduced expression of
UGT1A1 [34]. In human liver microsomes, glucuronidation of
SN-38, the active metabolite of irinotecan, is less efficient in
microsomes harbouring UGT1A1*28 compared to wildtype
genotype [25]. Concordantly, individuals with one or more
UGT1A1*28 alleles experience higher risk of neutropenia from
irinotecan treatment at doses higher than 250 mg/m2 [35,36].
This polymorphism is also more common in Caucasians than
Asians, with an allelic frequency of about 30% in Caucasians and
10% in Asians [37]. Our data shows that UGT1A1*28 is
associated with reduced belinostat glucuronidation, which suggests
that patients with this genotype may potentially have higher
exposure to active belinostat resulting from impaired clearance of
belinostat. Though the clinical consequences of this higher
exposure with the recommended dose of belinostat are currently
unknown, higher toxicities to belinostat are expected. If this is
proven, UGT1A1 genotyping prior to belinostat therapy, as is
currently available for irinotecan, is a way to individualise therapy.
Whether UGT1A1*28 influences the pharmacokinetics and
more crucially the pharmacodynamics of belinostat in patients
remains to be studied; our data supports the need for such future
studies in patients. In addition, the relevance of other polymor-
phisms of UGT1A1 should be studied further, as there is
substantial ethnogeographical variability of UGT1A1 variants.
For example, UGT1A1*28 is less common in East Asians, where
UGT1A1*6 (Gly71R) is more common, and associated with
reduced enzymatic activity.
Given the significance of UGT1A1 in the metabolism of
belinostat, it would be important to study the potential interactions
of known UGT1A1 inhibitors and inducers on belinostat PK and
pharmacodynamics. This is especially pertinent when belinostat is
given in combination with irinotecan, a cytotoxic drug which also
undergoes glucuronidation by UGT1A1 [12]. In colorectal cancer
cell lines, the combination of belinostat and irinotecan was highly
synergistic, and it is conceivable that such a combination is
planned in patients with colorectal cancers in the near future.
Supporting Information
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